Three lessons from making 100% in three months

Intelligent Investor

Independent Financial Research

Three lessons from making 100% in three months. Acrux is the patent owner of a testosterone replacement therapy (TRT) called Axiron. When it gained FDA approval in 2010, its share price more than doubled from $1.80 to $4.40 over two years. But in January this year the FDA launched an investigation into the safety of TRT. Acrux's share price crashed back to 75 cents by June. We thought the stock was trading below its intrinsic value and upgraded to a Buy. Sentiment had changed by August, and the stock rocketed back towards $2.00 where we sold half our position. Finally, on September 17 an FDA committee recommended Axiron's labels should include extra risks. Acrux's share price fell nearly 20% in a day and we sold what remained of our position at $1.35, locking in a 110% profit including dividends. Read our top three lessons from the rollercoaster ride: (VIEW LINK)


Intelligent Investor
Intelligent Investor
Independent Financial Research

Intelligent Investor is an independent financial research service with a 14-year history of beating the market. Our value investing approach empowers Australians to make more informed decisions to build their long-term wealth. We off structural...

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.